Department of Ophthalmology, University of Kansas Medical Center, Prairie Village, Kansas, USA Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, USA.
Department of Ophthalmology, University of Kansas Medical Center, Prairie Village, Kansas, USA.
Br J Ophthalmol. 2014 Aug;98(8):1013-5. doi: 10.1136/bjophthalmol-2013-304477. Epub 2014 Mar 28.
Far-red/near-infrared phototherapy or photobiomodulation (PBM) has recently been reported to be an effective and non-invasive treatment method to inhibit lesions of diabetic retinopathy (DR) in animals. This study investigated the safety and efficacy of PBM in diabetic patients to treat non-center-involving diabetic macular oedema (NCDME).
This was a non-randomised, consecutive, case series, where 4 patients with type 2 diabetes with NCDME were treated for 160 s per day with PBM for 2-9 months. Demographic data including age, sex, HbA1c%, electronic ETDRS visual acuity, and retinal and macular thickness were measured using spectral domain ocular coherence tomography (SD-OCT) before and after treatment.
Four eyes of 4 patients were treated, with fellow eyes serving as untreated controls. Daily PBM treatment for only 80 s per treatment twice daily caused a significant reduction in focal retinal thickening in all 4 treated eyes. No adverse effects attributable to therapy were noted by the patients or study investigators during the study period.
PBM potentially offers a non-invasive and cost-effective therapeutic option for patients with NCDME. Further studies of this therapeutic option in DR are warranted.
远红/近红外光疗法或光生物调节（PBM）最近被报道为一种有效且非侵入性的治疗方法，可抑制动物糖尿病视网膜病变（DR）的病变。本研究调查了 PBM 在糖尿病患者中治疗非中心性糖尿病黄斑水肿（NCDME）的安全性和有效性。
这是一项非随机、连续、病例系列研究，4 例 2 型糖尿病伴 NCDME 的患者每天接受 PBM 治疗 160 秒，持续 2-9 个月。使用谱域眼部相干断层扫描（SD-OCT）在治疗前后测量人口统计学数据，包括年龄、性别、HbA1c%、电子 ETDRS 视力和视网膜及黄斑厚度。
4 例患者的 4 只眼接受了治疗，对侧眼作为未治疗对照。每日 PBM 治疗两次，每次 80 秒，所有 4 只治疗眼的局灶性视网膜增厚均显著减少。在研究期间，患者或研究人员均未注意到与治疗相关的不良反应。
PBM 可能为 NCDME 患者提供一种非侵入性且具有成本效益的治疗选择。需要进一步研究这种治疗选择在 DR 中的应用。
